Interventional Glaucoma

SpyGlass Pharma completed enrollment in a Phase 1/2 trial evaluating its drug delivery platform for glaucoma and ocular hypertension. Designed for implantation during cataract surgery, the platform delivers bimatoprost to lower intraocular pressure for up to 3 years.

This retrospective cohort study was designed to provide further information on the association between BP parameters and VF progression over time.

While anxiety and depression may cause vision loss, physicians can offer hope

Moon Jeong Lee, MD, shares how volunteering in geriatric care shaped her career path.

Ripple will lead preclinical development of RTC-620 while AbbVie will lead the clinical and commercialization activities upon exercise of option-to-license agreement.

According to the company, topline results will be presented at the 2024 American Academy of Ophthalmology Annual Meeting, being held October 18 to 21 in Chicago, Illinois.

German researchers found that their study results suggest that the effect of glaucoma on the elapsed time depends on disease progression. This uncertainty during everyday navigation tasks may adversely affect patients’ quality of life.

Common glaucoma treatments may worsen ocular surface disease and meibomian gland dysfunction, leading to discomfort, redness, and even poor treatment compliance.

Push to identify biomarkers for earlier diagnosis, new therapeutic targets.

Research by investigators at Trinity College in Dublin shows how the gene therapy conferred significant benefit in animal models, and in human cells derived from people with glaucoma.

In the case study, a 63-year-old patient presented with severe acute pain in the right eye, which was diagnosed as a pupillary block leading to acute angle closure glaucoma.

According to researchers at Nanyang Technology University Singapore, smart contact lenses can be used to correct vision, monitor the health of the user, and flag and treat diseases for patients diagnosed with chronic health conditions such as glaucoma and diabetes.

Rationale for delving into this topic is the recent studies that have reported that active and healthy living can reduce IOP.

According to a study by a team of Korean researchers, published in BMC Ophthalmology, investigators conducted a retrospective study to examine the prevalence and clinical characteristics of ocular allergy in glaucoma patients using brinzolamide 1.0%/brimonidine 0.2% fixed combination (BBFC), with and without concurrent β-blocker.

Going forward, the company will operate under the Ocuvex name, building on Visiox's commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals.

During a recent Ophthalmology Times Case-Based Roundtable discussion, Albert S. Khouri, MD, shared his pearls in proactive glaucoma management.

Statin use was linked with increased glaucoma likelihood in the overall adult All of Us Research Program population with hyperlipidemia, in individuals with optimal or high LDL-C levels, and in individuals from 60 to 69 years old.

The microRNA(miR)-17-92 cluster is known to play an important role in cell signaling, but its specific functions in the eye are not well understood. The researchers’ focus lies in gaining insights into the mechanisms of miR-17-92 cluster members and their effects on IOP.

According to the company, its ViaLase Laser combines state-of-the-art femtosecond laser technology with micron-level image guidance to deliver the first femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT), marking a shift in glaucoma care.

iStent implantations increased sharply, whereas trabeculectomies saw a decline.

Researchers note work may lead to targets for conventional outflow pathway therapies.

According to the company, the Denali trial is evaluating NCX 470 safety and efficacy in patients with open-angle glaucoma or ocular hypertension and topline results continue to be expected in H2 2025

Therapeutics can prevent vision loss and neurodegeneration in patients.

Researchers indicate that minimally invasive treatment with NurExon Biologic’s ExoPTEN showed functional restoration of damaged eyes to healthy levels in animals.

According to the company, FYSX is the first non-pharmacological, non-surgical treatment designed to lower IOP for glaucoma patients.

Technology offers increased usability, safety, and accuracy in MIGS procedures.

The deal included a total upfront consideration of $81 million, including a cash payment of approximately $65 million.

The patient-facing brochure serves as a vehicle to help ECPs review the solution’s information and prescription filling process with patients during and after an office visit, and the website serves as an additional resource and reference once the patient returns home.